Advertisement
Canada markets open in 9 hours 2 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7319
    -0.0002 (-0.02%)
     

  • CRUDE OIL

    83.43
    +0.07 (+0.08%)
     

  • Bitcoin CAD

    91,208.63
    +336.20 (+0.37%)
     

  • CMC Crypto 200

    1,435.43
    +20.67 (+1.46%)
     

  • GOLD FUTURES

    2,340.50
    -1.60 (-0.07%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,728.25
    +121.50 (+0.69%)
     

  • VOLATILITY

    15.69
    -16.94 (-51.92%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,409.09
    +856.93 (+2.28%)
     

  • CAD/EUR

    0.6832
    -0.0004 (-0.06%)
     

Disclosure of voting rights for Chairman of the Board

PCI Biotech Holding ASA
·1 min read

Oslo, 27 May 2021. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn.

Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 28 May 2021. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 5,887,479 additional shares. In total, Mr. Bøhn will represent and vote for 16.1 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 28 May 2021.

This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757